MSB 1.01% 98.0¢ mesoblast limited

Agree. There are also markets for other lung diseases or...

  1. 258 Posts.
    lightbulb Created with Sketch. 663
    Agree. There are also markets for other lung diseases or complications of lung injury, COPD, sepsis etc.

    Also agree that it would be nice to see readouts of 12 month secondary outcome measures such as pulmonary symptoms.

    Let's hope@Bazsa 's intuition is right that this announcement may be preparing the market for a more substantial announcement including feed back from FDA in regards to the final potency assay. I thought this may be the case myself because the COVID ARDS trial will not commence until the potency assays (CMC) issues addressed.


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
98.0¢
Change
-0.010(1.01%)
Mkt cap ! $1.118B
Open High Low Value Volume
$1.00 $1.01 98.0¢ $4.720M 4.751M

Buyers (Bids)

No. Vol. Price($)
10 171759 98.0¢
 

Sellers (Offers)

Price($) Vol. No.
99.0¢ 16000 1
View Market Depth
Last trade - 16.10pm 25/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.